Evaluation of the beneficial effects of pemafibrate in hypertriglyceridemia with or without alcohol drinking (PAR-CHAT: PARmodia-CHikushi Anti-dyslipidemia Trial)
Pemafibrate improves TG, HDL-C, hepatic biomarkers and hypertriglyceridemia regardless of alcohol consumption and is safe. Increase of LDL-C was suppressed in patients treated with statins.
Authors
- Akira Kawamura (ORCID: https://orcid.org/0000-0003-3171-8413)
- Yosuke Takamiya
- Chiyori Imanaga
- Amane Ike
- Hidenori Urata
Institutions
- Fukuoka University (JP)
Publication Details
- Journal
- International Journal of Cardiology Cardiovascular Risk and Prevention
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1016/j.ijcrp.2024.200359
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kowa Company
- Fukuoka University